Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Valerio Therapeutics (ALVIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.426x
Based on the latest financial reports, Valerio Therapeutics (ALVIO) has a cash flow conversion efficiency ratio of 0.426x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.60 Million) by net assets (€-8.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Valerio Therapeutics - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Valerio Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Valerio Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valerio Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northern Superior Resources Inc
OTCQB:NSUPF
|
-0.989x |
|
An Phat Holdings JSC
VN:APH
|
0.051x |
|
Ferrum S.A.
BA:FERR
|
-0.007x |
|
Nerdy Inc
NYSE:NRDY
|
-0.065x |
|
GRIGEO AB EO -29
F:WM8
|
N/A |
|
Columbus Acquisition Corp Unit
NASDAQ:COLAU
|
-0.002x |
|
UEM Edgenta Bhd
KLSE:1368
|
0.028x |
|
Pacific Construction Co Ltd
TW:2506
|
0.015x |
Annual Cash Flow Conversion Efficiency for Valerio Therapeutics (2005–2024)
The table below shows the annual cash flow conversion efficiency of Valerio Therapeutics from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-8.27 Million | €-12.46 Million | 1.508x | +220.02% |
| 2023-12-31 | €14.80 Million | €-18.60 Million | -1.256x | -196.24% |
| 2022-12-31 | €22.27 Million | €-9.44 Million | -0.424x | -62.95% |
| 2021-12-31 | €32.94 Million | €-8.57 Million | -0.260x | -61.51% |
| 2020-12-31 | €29.04 Million | €-4.68 Million | -0.161x | +64.01% |
| 2019-12-31 | €17.20 Million | €-7.70 Million | -0.448x | -80.42% |
| 2018-12-31 | €45.40 Million | €-11.27 Million | -0.248x | +56.24% |
| 2017-12-31 | €49.87 Million | €-28.28 Million | -0.567x | -202.99% |
| 2016-12-31 | €94.09 Million | €-17.61 Million | -0.187x | +16.77% |
| 2015-12-31 | €102.80 Million | €-23.12 Million | -0.225x | -255.14% |
| 2014-12-31 | €121.97 Million | €-7.72 Million | -0.063x | +96.66% |
| 2013-12-31 | €7.44 Million | €-14.09 Million | -1.895x | -57.99% |
| 2012-12-31 | €11.74 Million | €-14.08 Million | -1.199x | -135.05% |
| 2011-12-31 | €22.90 Million | €-11.68 Million | -0.510x | -380.55% |
| 2010-12-31 | €18.85 Million | €3.43 Million | 0.182x | +113.24% |
| 2009-12-31 | €12.76 Million | €-17.53 Million | -1.374x | -34.94% |
| 2008-12-31 | €27.22 Million | €-27.71 Million | -1.018x | -622.69% |
| 2007-12-31 | €46.49 Million | €-6.55 Million | -0.141x | +78.05% |
| 2006-12-31 | €18.97 Million | €-12.17 Million | -0.642x | -131.34% |
| 2005-12-31 | €29.56 Million | €-8.20 Million | -0.277x | -- |